<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00125723</url>
  </required_header>
  <id_info>
    <org_study_id>20030218</org_study_id>
    <nct_id>NCT00125723</nct_id>
  </id_info>
  <brief_title>FIRST - Study of Pegfilgrastim Administered in the First and Subsequent Cycles of Myelosuppressive Chemotherapy</brief_title>
  <official_title>A Multicenter, Open-label, Phase 4 Study of Pegfilgrastim Administered in the First and Subsequent Cycles of Myelosuppressive Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the impact of first and subsequent cycle pegfilgrastim
      on neutropenia events (such as hospitalizations, dose reductions and delays) in patients
      receiving myelosuppressive chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">December 2005</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>dose delays and dose reductions and neutropenic events</measure>
    <time_frame>during treatment</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2252</enrollment>
  <condition>Neutropenia</condition>
  <arm_group>
    <arm_group_label>No Intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>PI Discretion</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PI Discretion</intervention_name>
    <description>PI Discretion</description>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_label>No Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: - Pathologically confirmed diagnosis of the following malignancies:
        breast, non-Hodgkin's lymphoma (NHL), Hodgkin's disease, ovarian, colorectal, lung or other
        - Planned administration of a new myelosuppressive every 14 (q14), q21, or q28 day
        chemotherapy - Written informed consent for participation in the study before any
        study-specific procedures are performed, including screening and registration Exclusion
        Criteria: - Planned concomitant therapeutic radiation - Diagnosis of acute or chronic
        leukemia or myelodysplastic syndrome - Prior stem-cell transplantation (includes
        bone-marrow transplantation) - Medical diagnosis of chronic neutropenia of any cause not
        related to cancer - Current cytotoxic, biologic, or immunologic therapy for unrelated
        conditions - Subject has active infection requiring treatment - Known HIV-positive subjects
        - Subject of child-bearing potential is evidently pregnant (e.g., positive HCG test) or is
        breast feeding - Subject of child-bearing potential is not using adequate contraceptive
        precautions - Known sensitivity to E. coli derived drug products (e.g., filgrastim,
        HUMULIN速 insulin, L-asparaginase, HUMATROPE速 growth hormone, INTRON A速) - Any psychiatric,
        addictive or other kind of disorder which compromises the ability of the subject to give
        written informed consent and/or to comply with study protocol procedures - Subject is
        currently enrolled in, or has not yet completed at least 30 days since ending another
        device or drug trial(s) or is receiving, or plans to receive, other investigational
        agent(s) not approved by the Food and Drug Administration (FDA)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <results_reference>
    <citation>Noga SJ, Choksi JK, Ding B, Dreiling L, Ozer H. Low incidence of neutropenic events in patients with lymphoma receiving first-cycle pegfilgrastim with chemotherapy: results from a prospective community-based study. Clin Lymphoma Myeloma. 2007 May;7(6):413-20.</citation>
    <PMID>17621407</PMID>
  </results_reference>
  <results_reference>
    <citation>Ozer H, Mirtsching B, Rader M, Luedke S, Noga SJ, Ding B, Dreiling L. Neutropenic events in community practices reduced by first and subsequent cycle pegfilgrastim use. Oncologist. 2007 Apr;12(4):484-94.</citation>
    <PMID>17470691</PMID>
  </results_reference>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2005</study_first_submitted>
  <study_first_submitted_qc>August 1, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2005</study_first_posted>
  <last_update_submitted>December 22, 2010</last_update_submitted>
  <last_update_submitted_qc>December 22, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2010</last_update_posted>
  <responsible_party>
    <name_title>Global Development Leader</name_title>
    <organization>Amgen Inc.</organization>
  </responsible_party>
  <keyword>Phase 4 Clinical Trial</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Neulasta速</keyword>
  <keyword>Oncology</keyword>
  <keyword>Malignancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

